Last reviewed · How we verify
High-dosage SARS-CoV-2 vaccine
This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles.
This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles. Used for Prevention of COVID-19 caused by SARS-CoV-2.
At a glance
| Generic name | High-dosage SARS-CoV-2 vaccine |
|---|---|
| Also known as | CoronaVac |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains chemically inactivated whole SARS-CoV-2 virions that cannot replicate. When administered at higher doses than standard formulations, it aims to elicit a stronger humoral and cellular immune response, generating neutralizing antibodies and T-cell responses against viral spike and other structural proteins. This enhanced immunogenicity is intended to provide improved protection against infection and severe COVID-19.
Approved indications
- Prevention of COVID-19 caused by SARS-CoV-2
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Myalgia
- Headache
Key clinical trials
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (PHASE1, PHASE2)
- A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection (PHASE1, PHASE2)
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19 (PHASE1, PHASE2)
- Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults (PHASE1, PHASE2)
- The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus (PHASE1)
- A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dosage SARS-CoV-2 vaccine CI brief — competitive landscape report
- High-dosage SARS-CoV-2 vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI